Toll-like Receptors, Tissue Injury, and Tumourigenesis

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2010 Sep 28

PMID 20871832

Citations 35

Authors

Savvas Ioannou

Michael Voulgarelis

Affiliations

Soon will be listed here.

Abstract

Toll-like receptors (TLRs) belong to a class of molecules known as pattern recognition receptors, and they are part of the innate immune system, although they modulate mechanisms that impact the development of adaptive immune responses. Several studies have shown that TLRs, and their intracellular signalling components, constitute an important cellular pathway mediating the inflammatory process. Moreover, their critical role in the regulation of tissue injury and wound healing process as well as in the regulation of apoptosis is well established. However, interest in the role of these receptors in cancer development and progression has been increasing over the last years. TLRs are likely candidates to mediate effects of the innate immune system within the tumour microenvironment. A rapidly expanding area of research regarding the expression and function of TLRs in cancer cells and its association with chemoresistance and tumourigenesis, and TLR-based therapy as potential immunotherapy in cancer treatment is taking place over the last years.

Citing Articles

TLR4 Downregulation Identifies High-Risk HPV Infection and Integration in H-SIL and Squamous Cell Carcinomas of the Uterine Cervix.

Santoro A, Angelico G, Arciuolo D, Scaglione G, Urtueta B, Aquino G Curr Issues Mol Biol. 2024; 46(10):11282-11295.

PMID: 39451550 PMC: 11506170. DOI: 10.3390/cimb46100670.

The Role of Natural Products from Herbal Medicine in TLR4 Signaling for Colorectal Cancer Treatment.

Luo Y, Zhang G, Hu C, Huang L, Wang D, Chen Z Molecules. 2024; 29(12).

PMID: 38930793 PMC: 11206024. DOI: 10.3390/molecules29122727.

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies.

Lesniak M, Lipniarska J, Majka P, Kopyt W, Lejman M, Zawitkowska J Vaccines (Basel). 2023; 11(2).

PMID: 36851155 PMC: 9967151. DOI: 10.3390/vaccines11020277.

Targeting toll-like receptor 7/8 for immunotherapy: recent advances and prospectives.

Sun H, Li Y, Zhang P, Xing H, Zhao S, Song Y Biomark Res. 2022; 10(1):89.

PMID: 36476317 PMC: 9727882. DOI: 10.1186/s40364-022-00436-7.

Investigation of Toll-like Receptor-2, -3 and -4 Gene Expressions in Larynx Squamous Cell Carcinoma.

Eker C, Inan H, Celebi A, Gozen E, Karaman E Turk Arch Otorhinolaryngol. 2022; 60(3):121-127.

PMID: 36452243 PMC: 9667699. DOI: 10.4274/tao.2022.2022-6-17.

References

Miyake K . Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol. 2007; 19(1):3-10. DOI: 10.1016/j.smim.2006.12.002. View

Tsan M . Toll-like receptors, inflammation and cancer. Semin Cancer Biol. 2005; 16(1):32-7. DOI: 10.1016/j.semcancer.2005.07.004. View

Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M . Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci. 2007; 98(11):1790-4. PMC: 11158170. DOI: 10.1111/j.1349-7006.2007.00590.x. View

Re F, Strominger J . Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity. Immunobiology. 2004; 209(1-2):191-8. DOI: 10.1016/j.imbio.2004.03.005. View

Nieters A, Beckmann L, Deeg E, Becker N . Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk. Genes Immun. 2006; 7(8):615-24. DOI: 10.1038/sj.gene.6364337. View

Goriely S, Neurath M, Goldman M . How microorganisms tip the balance between interleukin-12 family members. Nat Rev Immunol. 2007; 8(1):81-6. DOI: 10.1038/nri2225. View

Pai R, Soreghan B, Szabo I, Pavelka M, Baatar D, Tarnawski A . Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8(3):289-93. DOI: 10.1038/nm0302-289. View

Nyirenda M, OBrien K, Sanvito L, Constantinescu C, Gran B . Modulation of regulatory T cells in health and disease: role of toll-like receptors. Inflamm Allergy Drug Targets. 2009; 8(2):124-9. DOI: 10.2174/187152809788462581. View

Chochi K, Ichikura T, Kinoshita M, Majima T, Shinomiya N, Tsujimoto H . Helicobacter pylori augments growth of gastric cancers via the lipopolysaccharide-toll-like receptor 4 pathway whereas its lipopolysaccharide attenuates antitumor activities of human mononuclear cells. Clin Cancer Res. 2008; 14(10):2909-17. DOI: 10.1158/1078-0432.CCR-07-4467. View

10.

Komai-Koma M, Jones L, Ogg G, Xu D, Liew F . TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A. 2004; 101(9):3029-34. PMC: 365739. DOI: 10.1073/pnas.0400171101. View

11.

Paik Y, Schwabe R, Bataller R, Russo M, Jobin C, Brenner D . Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology. 2003; 37(5):1043-55. DOI: 10.1053/jhep.2003.50182. View

12.

Zhou X, Jia W, Shen G, Qin H, Yu X, Chen L . Sequence variants in toll-like receptor 10 are associated with nasopharyngeal carcinoma risk. Cancer Epidemiol Biomarkers Prev. 2006; 15(5):862-6. DOI: 10.1158/1055-9965.EPI-05-0874. View

13.

Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H . Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst. 2003; 95(4):316-26. DOI: 10.1093/jnci/95.4.316. View

14.

Hansson G, Edfeldt K . Toll to be paid at the gateway to the vessel wall. Arterioscler Thromb Vasc Biol. 2005; 25(6):1085-7. DOI: 10.1161/01.ATV.0000168894.43759.47. View

15.

Re F, Strominger J . IL-10 released by concomitant TLR2 stimulation blocks the induction of a subset of Th1 cytokines that are specifically induced by TLR4 or TLR3 in human dendritic cells. J Immunol. 2004; 173(12):7548-55. DOI: 10.4049/jimmunol.173.12.7548. View

16.

McDermott E, ONeill L . Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6, and TAK-1. J Biol Chem. 2001; 277(10):7808-15. DOI: 10.1074/jbc.M108133200. View

17.

Huang B, Zhao J, Li H, He K, Chen Y, Chen S . Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005; 65(12):5009-14. DOI: 10.1158/0008-5472.CAN-05-0784. View

18.

Salaun B, Coste I, Rissoan M, Lebecque S, Renno T . TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006; 176(8):4894-901. DOI: 10.4049/jimmunol.176.8.4894. View

19.

Banchereau J, Steinman R . Dendritic cells and the control of immunity. Nature. 1998; 392(6673):245-52. DOI: 10.1038/32588. View

20.

Milkova L, Voelcker V, Forstreuter I, Sack U, Anderegg U, Simon J . The NF-kappaB signalling pathway is involved in the LPS/IL-2-induced upregulation of FoxP3 expression in human CD4+CD25high regulatory T cells. Exp Dermatol. 2009; 19(1):29-37. DOI: 10.1111/j.1600-0625.2009.00953.x. View